Ibritumomab Tiuxetan Plus Rituximab as Initial Therapy for Patients With High Tumor Burden, Indolent Histology Non-Hodgkin's Lymphoma
The objective of this study is to estimate the median progression -free survival for
patients receiving this regimen, along with the rate of complete response at 6 months,
toxicities associated with this regimen, and laboratory correlates. Subjects will receive
the Zevalin(Ibritumomab Tiuxetan) therapeutic regimen; then rituximab consolidation and
maintenance therapy every 3 months until disease progression.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
CT scans
before and after treatment. every 3 mo after
No
Brad S Kahl, MD
Principal Investigator
University of Wisconsin, Madison
United States: Institutional Review Board
HO04405
NCT00582166
September 2004
March 2013
Name | Location |
---|---|
University of Wisconsin | Madison,, Wisconsin 53792-5666 |